TY  - JOUR
AU  - Juhász, Szilvia
AU  - Balogh, Dávid
AU  - Hajdú, Ildikó
AU  - Burkovics, Péter
AU  - Villamil, MA
AU  - Zhuang, Z
AU  - Haracska, Lajos
TI  - Characterization of human Spartan/C1orf124, an ubiquitin-PCNA interacting regulator of DNA damage tolerance
JF  - NUCLEIC ACIDS RESEARCH
J2  - NUCLEIC ACIDS RES
VL  - 40
PY  - 2012
IS  - 21
SP  - 10795
EP  - 10808
PG  - 14
SN  - 0305-1048
DO  - 10.1093/nar/gks850
UR  - https://m2.mtmt.hu/api/publication/2106876
ID  - 2106876
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Nikolényi, Alíz
AU  - Uhercsák, Gabriella
AU  - Csenki, Melinda
AU  - Hamar, Sándor
AU  - Csörgő, Erika
AU  - Tánczos, Ervin
AU  - Thurzó, László
AU  - Brodowicz, Thomas
AU  - Wagnerova, Maria
AU  - Kahán, Zsuzsanna
TI  - Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy
JF  - PATHOLOGY AND ONCOLOGY RESEARCH
J2  - PATHOL ONCOL RES
VL  - 18
PY  - 2012
IS  - 1
SP  - 61
EP  - 68
PG  - 8
SN  - 1219-4956
DO  - 10.1007/s12253-011-9417-4
UR  - https://m2.mtmt.hu/api/publication/1631866
ID  - 1631866
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Vermorken, JB
AU  - Remenár, Éva
AU  - van Herpen, C
AU  - Gorlia, T
AU  - Mesia, R
AU  - Degardin, M
AU  - Stewart, JS
AU  - Jelic, S
AU  - Betka, J
AU  - Preiss, JH
AU  - van den Weyngaert, D
AU  - Awada, A
AU  - Cupissol, D
AU  - Kienzer, HR
AU  - Rey, A
AU  - Desaunois, I
AU  - Bernier, J
AU  - Lefebvre, JL
TI  - Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
JF  - NEW ENGLAND JOURNAL OF MEDICINE
J2  - NEW ENGL J MED
VL  - 357
PY  - 2007
IS  - 17
SP  - 1695
EP  - 1704
PG  - 10
SN  - 0028-4793
DO  - 10.1056/NEJMoa071028
UR  - https://m2.mtmt.hu/api/publication/2825662
ID  - 2825662
N1  - CA EORTC 24971 TAX 323 Stu
AB  - Background Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head and neck. We compared TPF with PF as induction chemotherapy in patients with locoregionally advanced, unresectable disease. Methods We randomly assigned eligible patients between the ages of 18 and 70 years who had stage III or stage IV disease and no distant metastases to receive either TPF (docetaxel and cisplatin, day 1; fluorouracil by continuous infusion, days 1 to 5) or PF every 3 weeks for four cycles. Patients without progression of disease received radiotherapy within 4 to 7 weeks after completing chemotherapy. The primary end point was progression-free survival. Results A total of 358 patients underwent randomization, with 177 assigned to the TPF group and 181 to the PF group. At a median follow-up of 32.5 months, the median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF group (hazard ratio for disease progression or death in the TPF group, 0.72; P = 0.007). Treatment with TPF resulted in a reduction in the risk of death of 27% (P = 0.02), with a median overall survival of 18.8 months, as compared with 14.5 months in the PF group. There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group. The rates of death from toxic effects were 2.3% in the TPF group and 5.5% in the PF group. Conclusions As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck.
LA  - English
DB  - MTMT
ER  -